From a translational perspective, our findings support the notion that gestational age-specific components of AF, including enzymatic antioxidants such as SOD1 and SOD3, should be considered in the development of targeted nutritional and pharmacological interventions for at-risk neonates. The gene discussed is SOD1; the disease is atrial fibrillation.